Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
CD19 CAR-T is now a standard treatment option for relapsed/refractory Large B-cell lymphoma (LBCL) / Diffuse Large B-Cell Lymphoma (DLBCL), especially in second-line early relapse/refractory disease and in later-line salvage settings. Three CD19-directed products are central in Large B-cell lymphoma (LBCL) / Diffuse Large B-Cell Lymphoma (DLBCL) practice: axicabtagene ciloleucel, lisocabtagene maraleucel, and [tisagenlecleucel](brain://0P5YWHERJE2YAAYSkZKpRQ/TisagenlecleucelLargeBcellLymphomaLbclD…